<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01369472</url>
  </required_header>
  <id_info>
    <org_study_id>125HPS11E</org_study_id>
    <nct_id>NCT01369472</nct_id>
  </id_info>
  <brief_title>Evaluating Dose-proportionality of Dilatrend Suspended-Release Capsule</brief_title>
  <official_title>A Randomized, Open-label, Single Dose, Dose-rising 10-sequence, 3-period Balanced Incomplete Blocked Clinical Trial to Evaluate Dose-proportionality of Dilatrend SR in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate dose-proportionality of Dilatrend SR 8mg, 16mg, 32mg,
      64mg, 128mg in healthy male volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-proportionality</measure>
    <time_frame>0(predose), 1, 2, 4, 5, 6, 8, 12, 16, 24, 36 and 48h</time_frame>
    <description>AUClast</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-proportionality</measure>
    <time_frame>0(predose), 1, 2, 4, 5, 6, 8, 12, 16, 24, 36 and 48h</time_frame>
    <description>AUC0-∞</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-proportionality</measure>
    <time_frame>0(predose), 1, 2, 4, 5, 6, 8, 12, 16, 24, 36 and 48h</time_frame>
    <description>Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-proportionality</measure>
    <time_frame>0(predose), 1, 2, 4, 5, 6, 8, 12, 16, 24, 36 and 48h</time_frame>
    <description>Tmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-proportionality</measure>
    <time_frame>0(predose), 1, 2, 4, 5, 6, 8, 12, 16, 24, 36 and 48h</time_frame>
    <description>t½β</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>0(predose), 4, 8, 12, 24, 36, 48h and follow-up visit(22d±1d)</time_frame>
    <description>Adverse Event/Serious Adverse Event monitoring Physical Examination, Vital Sign, 12-lead ECG, Lab Tests</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Chronic Stable Angina</condition>
  <arm_group>
    <arm_group_label>Dilatrend SR capsule 8mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dilatrend SR capsule 16mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dilatrend SR capsule 32mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dilatrend SR capsule 64mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dilatrend SR capsule 128mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dilatrend SR capsule</intervention_name>
    <description>single oral administration in period 1 or 2, 3 for each sequential group.</description>
    <arm_group_label>Dilatrend SR capsule 8mg</arm_group_label>
    <arm_group_label>Dilatrend SR capsule 16mg</arm_group_label>
    <arm_group_label>Dilatrend SR capsule 32mg</arm_group_label>
    <arm_group_label>Dilatrend SR capsule 64mg</arm_group_label>
    <arm_group_label>Dilatrend SR capsule 128mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age range 20 to 54 years, Body mass index of ≥19 and ≤26 healthy male volunteers

          2. Able to participate in all procedure

          3. SBP 90-140 mmHg, DBP 60-90 mmHg, Pulse rate 55-95 times/min

          4. Have given written informed consent

        Exclusion Criteria:

          1. Have history of significant cardiovascular, hepatic, renal, pulmonary, hematologic,
             gastrointestinal, endocrine, musculoskeletal neurologic disease

          2. Have history of gastrointestinal disease(Crohn's disease, gastrointestinal ulcer) or
             surgery(except for Appendectomy, Hernia)

          3. Have allergy or hypersensitivity to carvedilol or any component of the
             formulation(aspirin, antibiotics)

          4. Have history of drug abuse. A positive test for any drug(amphetamine, barbiturates,
             cocaine, opiates, benzodiazepines, THC, methadone, ect.) included in the urine drug
             screen.

          5. Have herbal drug within 30days prior to the first IP administration, have ETC within
             14days prior to the first IP administration, have OTC 7days prior to the first IP
             administration.

          6. Have diet which may influence on the absorption, distribution, metabolism or excretion
             of drug(s), (Drinking over 1L of grapefruit juice within 7days prior to the first IP
             administration)

          7. Have received an investigational drug within 60 days prior to the first IP
             administration

          8. Have donated whole blood within 60 days prior or donation plasma within 30 days prior
             to the first IP administration

          9. Have any metabolic enzyme including or inhibiting drugs like barbiturates within 30
             days prior to the first IP administration.

         10. A heavy caffeine/alcohol consumer or a heavy smoker(caffeine &gt; 5 units/days. alcohol
             &gt;21 units/week (1 unit=pure alcohol 10mL), Cigarette &gt; 10 Cigarettes/day) or alcohol
             abuse.

         11. Positive for Hepatitis B, Hepatitis C, HIV or syphilis
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>54 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>KS Bae, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medcial Center</name>
      <address>
        <city>Songpa-gu</city>
        <state>Seoul</state>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2011</study_first_submitted>
  <study_first_submitted_qc>June 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2011</study_first_posted>
  <last_update_submitted>February 13, 2012</last_update_submitted>
  <last_update_submitted_qc>February 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2012</last_update_posted>
  <responsible_party>
    <name_title>Jin Kim / Director</name_title>
    <organization>Clincal Research Department</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angina, Stable</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carvedilol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

